Papers by Jill L Colquitt
Health Technology …, Jan 1, 2010
... Birmingham Edgbaston Birmingham B15 2TT UK Authors Janine Dretzke 1 Jeff Round 2 Martin Conno... more ... Birmingham Edgbaston Birmingham B15 2TT UK Authors Janine Dretzke 1 Jeff Round 2 Martin Connock 1 Sandy Tubeuf 2 Mary Pennant 1 Anne Fry-Smith 1 Claire Hulme 2 Chris McCabe 2 Catherine Meads 1 1 Unit of Public Health ...
British Journal of Ophthalmology, 2007
Aims: To assess the clinical effectiveness of pegaptanib sodium and ranibizumab for neovascular a... more Aims: To assess the clinical effectiveness of pegaptanib sodium and ranibizumab for neovascular age-related macular degeneration (AMD). Methods: A systematic review of randomised controlled trials (RCTs) identified through searching 12 electronic databases, bibliographies and consultation with experts and manufacturers. RCTs were eligible if they assessed the effects of pegaptanib or ranibizumab with best supportive care, sham injection or photodynamic therapy (PDT) on patients with subfoveal choroidal neovascularisation associated with wet AMD and examined outcomes including visual acuity and adverse events. Results: Three RCTs of ranibizumab (MARINA, ANCHOR, FOCUS) and two of pegaptanib (VISION study) met the inclusion criteria. The RCTs included patients with different lesion types. The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. These differences appeared to be clinically significant. Although adverse events were common among those receiving pegaptanib or ranibizumab, they were considered mild to moderate in nature. Meta-analysis of ranibizumab trials and indirect comparison of the two drugs were not possible due to differences in the study populations' lesion types. However, results from the RCTs of ranibizumab tended to show a greater effect on visual acuity than results from the RCT of pegaptanib. Conclusions: Pegaptanib and ranibizumab appear to slow or stop the progression of neovascular AMD. Uncertainty remains over the relative benefits of pegaptanib compared with ranibizumab and other unlicensed drugs (eg, Avastin), due to the nature of the evidence. Head-to-head RCTs and economic evaluations comparing these alternatives are needed.
Diabetic Medicine, 2003
Aims The properties of rapid-acting insulin analogues are thought to be particularly appropriate... more Aims The properties of rapid-acting insulin analogues are thought to be particularly appropriate for use in continuous subcutaneous insulin infusion (CSII) or insulin pump therapy. We conducted a systematic review and meta-analysis of trials comparing rapid-acting insulin analogues with soluble insulin in CSII.Methods The following databases were searched (last search June 2002): MEDLINE 1985–2002; Embase 1980–2002; PubMed internet version, records added June 2001 to June 2002; Science Citation Index 1990–2002; BIOSIS 1999–2002; Web of Science Proceedings 1990–2002; and the Cochrane Library, including DARE and the HTA databases. Randomized controlled trials and crossover studies with at least 10 weeks on each treatment were included. Data extraction and quality assessment were undertaken by one reviewer and checked by a second. A meta-analysis was undertaken using a random effects model.Results A significant improvement of 0.26% (95% confidence interval −0.47, −0.06%) in glycated haemoglobin was demonstrated with lispro. Some studies reported fewer hypoglycaemic episodes with analogue insulin but this varied according to the definitions used. No differences in insulin dosage or weight were seen. Two studies reported patient preference, with analogues preferred in both. The extra cost per annum ranges from £72 (at 40 units per day) to £150 (at 84 units per day).Conclusions Insulin analogues result in a modest but significant reduction in HbA1c compared with soluble insulin when used in CSII, and are preferred by patients.
International Journal of Obesity, 2003
International Journal of Technology Assessment in Health Care, 2007
et al. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart... more et al. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation. Health Technol Assess 2005;9(45). Health Technology Assessment 2005; Vol. 9: No. 45 (Executive summary)
The clinical and cost-effectiveness of once daily versus more frequent use of same potency topica... more The clinical and cost-effectiveness of once daily versus more frequent use of same potency topical corticosteroids for people with atopic eczema.
Uploads
Papers by Jill L Colquitt